You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK

Showing 26 - 50 of 1,010
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer Trial in Beijing (Ensartinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Beijing, Beijing, China
  • +1 more
Aug 17, 2022

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Beijing, Beijing, China
    Department of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022

Patient Journey With Advanced Lung Cancer Positive for ALK

Recruiting
  • Carcinoma, Non-Small-Cell Lung
    • Fortaleza, Ceará, Brazil
    • +4 more
    Sep 26, 2022

    ALK Positive Tumors Trial (ceritinib)

    No longer available
    • ALK Positive Tumors
    • (no location specified)
    Nov 30, 2021

    Non Small Cell Lung Cancer Trial in Changsha (IBI-322 Plus Lenvatinib and Platinum)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • IBI-322 Plus Lenvatinib and Platinum
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 14, 2022

    NSCLC, Stage III, ALK-rearrangement Trial in Worldwide (Brigatinib, Durvalumab)

    Not yet recruiting
    • NSCLC, Stage III
    • ALK-rearrangement
    • Angers, France
    • +19 more
    Feb 8, 2023

    Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer

    Active, not recruiting
    • Non-Small-Cell Lung Carcinoma
    • New York, New York
      Pfizer Inc
    Apr 12, 2022

    Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

    Withdrawn
    • Advanced Malignant Neoplasm
    • +10 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 15, 2022

    Chemotherapy Combined With Immunotherapy or Chemotherapy

    Completed
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 9, 2022

    Melanoma Trial in United States (Ensartinib, ALKATI by Customized Nanostring Assay)

    Active, not recruiting
    • Melanoma
    • Middletown, New Jersey
    • +3 more
    Jan 25, 2022

    ALK+ Anaplastic Large Cell Lymphoma Trial in Wien (Brentuximab vedotin, Imatinib)

    Terminated
    • ALK+ Anaplastic Large Cell Lymphoma
    • Wien, Austria
      Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abte
    Feb 15, 2022

    Geographic Atrophy, Age Related Macular Degeneration, AMD Trial in Somerville (ALK-001 oral capsule, Placebo oral capsule)

    Active, not recruiting
    • Geographic Atrophy
    • +3 more
    • ALK-001 oral capsule
    • Placebo oral capsule
    • Somerville, Massachusetts
      Coordinating Center
    Feb 15, 2022

    Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

    Active, not recruiting
    • ALK-Positive Anaplastic Large Cell Lymphoma
    • RNAseq
    • Toulouse, France
      IUCT-Oncopole University Hospital
    Jul 3, 2023

    ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

    Completed
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Sep 23, 2021

    Allergic Rhinitis Trial in Hørsholm (Observational)

    Recruiting
    • Allergic Rhinitis
    • Observational
    • Hørsholm, Hovedstaden, Denmark
      ALK Abello
    May 26, 2023

    NSCLC Trial in Tianjin (Ensartinib, Placebo)

    Recruiting
    • Non-small Cell Lung Cancer
    • Tianjin, China
      TianJin Medical University Cancer Institute & Hospital
    Jul 13, 2022

    Lung Cancer, NSCLC, Brain Metastases Trial (Alectinib, Stereotactic Radiosurgery)

    Not yet recruiting
    • Lung Cancer
    • +2 more
    • (no location specified)
    Aug 4, 2023

    NSCLC Trial in Seoul (Brigatinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Apr 29, 2022

    Solid Tumor, NSCLC Metastatic Trial in Guanzhou (Ensartinib)

    Recruiting
    • Solid Tumor
    • Non-Small Cell Lung Cancer Metastatic
    • Guanzhou, Guangdong, China
      Sun yat-sen Univerisity Cancer Center
    Nov 22, 2021

    Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

    Withdrawn
    • Non-Small Cell Lung Cancer
    • InVisionFirst-Lung ctDNA assay
    • Los Angeles, California
    • +2 more
    Sep 16, 2022

    Non Small Cell Lung Cancer Trial in Goyang-si (Brigatinib)

    Recruiting
    • Non Small Cell Lung Cancer
    • Goyang-si, Gyeonggi-do, Korea, Republic of
      National Cancer Center
    Apr 4, 2022

    Non Small Cell Lung Cancer Trial (TGRX-326, Crizotinib)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • (no location specified)
    Oct 8, 2023

    Lung Cancer, EGFR Gene Mutation, EGFR Trial in Charlottesville (Sensus Smartwatch Application, RX Cap, Fitbit Sense)

    Recruiting
    • Lung Cancer
    • +3 more
    • Sensus Smartwatch Application
    • +3 more
    • Charlottesville, Virginia
      University of Virginia
    Aug 26, 2022

    Ensatinib in alK-positive Patients Undergoing Initial Treatment

    Recruiting
    • ALK Positive
    • +2 more
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Nov 16, 2021